Intrathecal adrabetadex reduced the risk of death by 55% compared with weighted external controls in patients whose ...
Neladalkib (Nelkarmi) is now FDA-approved for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib alone or with 2 or more ALK TKIs plus platinum-based ...
Five new treatments across rheumatology, nephrology, cardiology, dermatology, and endocrinology await FDA approval decisions before year-end 2026.
More than a year of nonstop spread and more than 5400 cases this year mean unvaccinated children face a risk the country hasn’t seen in decades ...
Breckenridge Pharmaceutical Inc has recalled 1 lot (PK25110035) of 60mg propranolol hydrochloride extended-release capsules distributed nationwide from October 26 to November 4, 2026, due to potential ...
During the 2026 ACAAI Annual Scientific Meeting, Scott Commins, MD, PhD, describes the clinical nuances and presentation of ...
Supported by phase 3 PREVAIL data, the dual-binding nanobody complement C5 inhibitor provides rapid, sustained functional ...
A survey presented at ACAAI 2026 shows 77% of US allergists attempt to wean patients off asthma biologics after sustained ...
Oral remibrutinib demonstrated early and sustained efficacy through 52 weeks across 3 CIndU subtypes in the phase 3 RemIND ...
Research presented at ACAAI 2026 evaluates stock versus personal epinephrine supply requirements, epinephrine availability, ...
The updated label incorporates head-to-head efficacy data showing superior improvements in functional class, symptom burden, and outflow tract gradient with aficamten vs metoprolol in adults with ...